Cargando…
Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption. Continued use of denosumab results in a potent and sustained decreas...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Endocrine Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081316/ https://www.ncbi.nlm.nih.gov/pubmed/35417954 http://dx.doi.org/10.3803/EnM.2021.1369 |